SEND TO A COLLEAGUE | FAQs | REQUEST MORE INFORMATION

The CSL Behring Commitment

CSL Behring demonstrates its commitment to patients in many ways. These include:

Sponsoring programs and activities that benefit people with bleeding disorders
Working with government authorities to help make sure patients have access to care
Improving and expanding educational and outreach efforts
Funding medical research

Featured programs and services of the CSL Behring commitment include:

The Reimbursement Resource Center provides the following to patients and healthcare professionals:

Information on medical service costs
Health insurance reimbursement for the CSL Behring product line
Coverage trends
Patient assistance
And more…

You may also call the CSL Behring Reimbursement Answerline at 1-800-676-4266 for assistance with individual case inquiries.

CSL Behring Foundation for Research and Advancement of Patient Health

This is the only nonprofit foundation dedicated exclusively to charitable, scientific, and educational endeavors that benefit the bleeding disorders community. The Foundation provides grants for research projects and community initiatives that advance the standard of care for people with bleeding disorders.

CSL Behring Assurance

A gap in insurance shouldn’t mean a gap in treatment. This program helps to ensure that people who rely on CSL Behring recombinant and plasma-derived therapies can continue to receive treatment — even if they experience a lapse in third-party, private health insurance.

Patient Assistance

The Patient Assistance Program provides medically necessary therapies to qualified patients who are uninsured or underinsured or for those individuals who cannot afford their prescribed therapy.

Medical Affairs
Phone: 1-800-504-5434
Fax: 610-878-4007
E-mail: medinfona@CSLbehring.com

Medical Information
North America Headquarters
CSL Behring
P.O. Box 61501
1020 First Avenue
King of Prussia, PA 19406 USA

Important Safety Information

RiaSTAP^®, Fibrinogen Concentrate (Human), is indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

The effectiveness of RiaSTAP is based on maximum clot firmness (MCF), which measures the structural integrity of a clot, reflecting the underlying effectiveness of the fibrinogen present to form a fibrin clot. There are no controlled trials demonstrating a direct benefit on treatment of bleeding episodes with RiaSTAP.

RiaSTAP is not indicated for dysfibrinogenemia.

RiaSTAP is contraindicated in individuals who have manifested severe immediate hypersensitivity reactions, including anaphylaxis to RiaSTAP or its components. Monitor patients for early signs of allergic or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment. Thrombotic events have been reported in patients receiving RiaSTAP; weigh the benefits of administration versus the risks of thrombosis.

RiaSTAP is made from pooled human plasma. Products made from human plasma may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

The most serious adverse reactions that have been reported in subjects in clinical studies who received RiaSTAP are thromboembolic episodes, including myocardial infarction and pulmonary embolism, and allergic-anaphylactic reactions. The most common adverse reactions observed are allergic reactions, including chills, fever, nausea, and vomiting. Monitor patients for early signs of allergic or hypersensitivity reactions and if necessary, discontinue administration.

Please see full prescribing information for RiaSTAP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.